Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Product/Service

Dr. Vince Clinical Research Opens Industry-Leading Clinical Pharmacology Unit


Dr. Vince Clinical Research (DVCR), today announced the launch of its new, world-class clinical pharmacology unit and headquarters in Overland Park, Kansas. The custom-built, green-inspired research complex was intentionally designed and engineered ? with significant investments in infrastructure, research-changing technologies, employee wellness and excellence and environmental sustainability ? to be the premier destination in the country for Phase I clinical studies.

Dedicated to Phase I Clinical Trials

"Our vision was to create the top clinical pharmacology unit in the U.S. that enables delivering faster and cleaner data to our biopharmaceutical clients," said Brad Vince, D.O., a 20-year industry veteran and founder, CEO and medical director. "To accomplish our goals and transform standard industry practices, we built one of the most innovative and technologically advanced Phase I sites ever."

The company leveraged a robust team of engineers and consultants to plan and construct the new facility and help ensure seamless deployment of the latest technologies for both the physical infrastructure of the 90-bed center and company operations and processes. These key technologies enable the company to deliver higher quality data more efficiently than current industry standards, including:

Investing in People

The company designed the facility to be one of the world's most luxurious research centers in order to deliver unrivaled study volunteer recruitment and retention. "However, the facility alone is not enough to create the optimal environment for conducting Phase I trials," Dr. Vince continued. "The team overseeing a trial is crucial to the execution and success of any clinical study, so we carefully and thoughtfully assembled one of the most experienced early phase leadership teams in the industry so we can provide unparalleled service to our sponsors and positively change the future of clinical research."

Website: https://sponsors.drvince.com

LinkedIn: https://www.linkedin.com/company/dr-vince-clinical-research/

About Dr. Vince Clinical Research

Dr. Vince Clinical Research (DVCR) is a world-class CRO (contract research organization) with a custom-built, green-designed headquarters and research complex encompassing three buildings in Overland Park, KS. DVCR's complex includes a 90-bed clinical pharmacology unit featuring a combination of luxurious and private research suites and a GMP-compliant pharmacy with positive and negative pressure compounding rooms. DVCR specializes in conducting clinical trials for both healthy normal volunteers and patient populations in a wide variety of early phase trials. By leveraging both technology and one of the country's most experienced leadership teams, DVCR provides Smarter, Faster Datatm to its biopharmaceutical clients.


These press releases may also interest you

at 20:25
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...

at 20:12
BCACC is pleased to announce that its Deputy Registrar, Kathy Lauriente, has been honoured with the Distinguished Service Award from Thompson Rivers University. The award recognizes stellar contributions to the University, community, and the public...

at 19:29
Suffolk DBT is proud to announce the completion of their initial expansion to accommodate the growing need for DBT therapy...

at 18:24
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference. On April 26, 2024, the hearing will commence 11:15 a.m. Members of the public may observe the hearing by videoconference, by...

at 17:55
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....

at 17:43
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...



News published on and distributed by: